Infliximab News and Research

RSS

Infliximab is a monoclonal antibody that blocks the action of a cytokine called tumor necrosis factor alfa. It is being studied in the treatment and prevention of weight loss and loss of appetite in patients with advanced cancer. It belongs to the family of drugs called monoclonal antibodies.

Juvenile immune arthritis – new treatments wanted

Juvenile immune arthritis (JIA) is a severely undertreated condition, and new medications are badly needed to relieve the signs and symptoms of the illness, according to a new study presented at the 2019 ACR/ARP Annual Meeting.

11 Nov 2019

Additional medications needed to control the symptoms of juvenile idiopathic arthritis

According to new research findings presented this week at the 2019 ACR/ARP Annual Meeting, there is a profound ongoing need for additional medications to control the signs and symptoms of juvenile idiopathic arthritis, despite the availability of several approved biologic disease-modifying antirheumatic drugs (biologics).

10 Nov 2019

Study reveals safety, efficacy of live zoster vaccine for people taking TNF inhibitors

According to new research findings presented this week at the 2019 ACR/ARP Annual Meeting, the live zoster virus vaccine is safe for people who are currently receiving tumor necrosis factor inhibitor (TNFi) biologic therapies for various indications.

10 Nov 2019

Study identifies genetic marker which could personalize treatment for Crohn's disease

The largest study ever to look at why an expensive and commonly used group of drugs fails some patients with Crohn's disease has identified a genetic marker which could individualize drug treatment.

7 Oct 2019

Common genetic variant explains why immunotherapy often fails in Crohn's disease

The reason why a commonly used range of immunotherapy drugs is not effective in some patients with Crohn’s disease has so far not been identified, until now.

7 Oct 2019

New therapeutic target for rheumatoid arthritis and type 2 diabetes

There is a growing body of knowledge that points that type 2 diabetes, a chronic disease where the blood sugar increases, is an inflammatory disease. The levels of certain inflammatory chemicals, dubbed as cytokines, are often higher in people with type 2 diabetes, than healthy people.

16 Sep 2019

Research suggests new way to improve the efficacy of arthritis drug

Attaching a removable lock to an arthritis drug can make it safer and more effective, according to a new study publishing June 13 in the open-access journal PLOS Biology led by Wen-Wei Lin of Kaohsiung Medical University, Taiwan.

From PLOS ONE 14 Jun 2019

Study: Biologic therapy did not reduce IBD-related hospitalizations and surgeries

The introduction of infliximab, the first biologic therapy approved for the treatment of inflammatory bowel diseases, did not result in lower rates of hospitalizations or intestinal surgeries among patients living with IBD in Ontario, according to a study published by authors from several Canadian hospitals and ICES in the journal Gut.

13 Jun 2019

Dermcidin in human sweat may contribute to pathogenesis of hidradenitis suppurativa

Dermcidin, an anti-microbial peptide normally found in human sweat, may play a role in the pathogenesis of this chronic skin disease hidradenitis suppurativa, according to a research team from the George Washington University.

26 Apr 2019

Toxic effects of drugs in the lungs 'more widespread than thought'

A systematic review of research has revealed that the toxic effects on the lung of drugs commonly taken to treat a range of common conditions is much more widespread than thought.

29 Oct 2018

Combination of NSAIDs and TNF inhibitors linked to reduced radiographic progression in AS patients

Celecoxib combined with TNF inhibitors was associated with the greatest reduction in radiographic progression.

14 Jun 2018

Celltrion Healthcare advocates early introduction of biologics for patients to improve clinical outcomes

At the International Society for Pharmacoeconomics and Outcomes Research 23rd Annual International Meeting in Baltimore, Celltrion Healthcare today advocated for healthcare systems to introduce biologics earlier in a patient’s treatment regimen in order to improve clinical outcomes.

22 May 2018

Genetic test to predict IBD severity in children

Inflammatory bowel disease (IBD) is a chronic relapsing inflammation of the gastrointestinal tract with abdominal pain and diarrhea being the most common symptoms. It can be challenging to diagnose as gastrointestinal complaints mimicking IBD are common.

26 Jul 2017

Study shows efficacy of biologics for mucosal healing in Crohn's disease and ulcerative colitis

Although anti-inflammatory treatments are quite effective at reducing symptoms in patients with Crohn's disease and ulcerative colitis, the mucosal lining of the intestine often remains ulcerated, and many patients still ultimately require surgery.

22 Mar 2017

New, low-cost biosimilar for IBD therapy shows efficacy and safety

Treatment of Crohn's disease and ulcerative colitis has been greatly improved by the introduction of biologic therapies such as infliximab (which targets tumour necrosis factor alpha), but at considerable cost.

3 Mar 2017

Researchers receive $2 million grant from PCORI to study effective treatment for children with KD

Kawasaki disease (KD) is an uncommon illness that affects blood vessels in the hearts of children

2 Feb 2017

Penn scientists develop combined medical and surgical care plan for managing Crohn's disease

The first published combined medical and surgical care plan for managing septic perianal Crohn's disease, a serious complication that occurs in around 40 percent of Crohn's disease patients, has been developed by researchers at Penn State College of Medicine.

23 Aug 2016

Generic biologic drugs appear to be as effective as brand-name versions

Generic forms of a biologic drug used to treat rheumatoid arthritis, inflammatory bowel disease and psoriasis appear to be as safe and effective as their brand-name counterparts, a new Johns Hopkins Bloomberg School of Public Health analysis suggests.

2 Aug 2016

Celltrion Healthcare commits to develop lab tests for evidence-based decision-making in anti-TNF treatment

Celltrion Healthcare, a global biopharmaceutical company, today announced its research commitment to develop laboratory tests that will determine both drug and anti-drug antibody levels in the blood, enabling physicians to identify when patients on an anti-tumour necrosis factor drug require a change of dose or a switch to a different treatment in the class.

5 Jul 2016

Factors other than just cost may influence prescribing of TNF inhibitors for RA patients

The results of a study presented today at the European League Against Rheumatism Annual Congress showed that a range of factors other than just cost may influence the prescribing of TNF inhibitors for patients with rheumatoid arthritis (RA).

13 Jun 2016